{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:33:11Z","timestamp":1740166391429,"version":"3.37.3"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Isr J Health Policy Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The devastating human and financial costs of the ongoing global opioid crisis underscore the need for comprehensive public health strategies, effective treatment programs, and robust policy interventions to mitigate its impact. Regarding Israel, numerous reports highlight a steady increase since 2000 in prescription opioid use and the shift to more potent opioids particularly fentanyl, particularly among more marginalized population groups. In response to growing concern in the country about the rise in prescription opioid use and the consequential risk of opioid use disorder, the Israeli government, together with the country\u2019s health service providers, implemented a series of measures to monitor and regulate opioid prescriptions and balance the need for effective pain management with the prevention of opioid abuse and its associated harms. A national opioid data monitoring system is being established, alongside the provision of addiction training for health professionals, the integration of treatment services for opioid use disorder into the nationalized primary healthcare system, and the expansion of harm reduction strategies to mitigate the health risks associated with opioid use. Additional funding for opioid-related research, and for the broader fields of addictions and mental health, is vital. In conclusion, the sum of the evidence suggests that Israel is not facing an \u201copioid crisis\u201d Continued commitment, resources, and innovative approaches will be crucial to ensure that the rising tide of opioid use in Israel, particularly during and in the aftermath of the ongoing war, will not become a tidal wave.<\/jats:p>","DOI":"10.1186\/s13584-024-00648-2","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T20:22:11Z","timestamp":1728591731000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prescription opioid use in Israel \u2013 the tide has risen, but it\u2019s not a tidal wave"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6486-4591","authenticated-orcid":false,"given":"Yehuda","family":"Neumark","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Rosca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"key":"648_CR1","unstructured":"Dydyk AM, Jain NK, Gupta M, Opioid Use D. 2024. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan\u2013. PMID: 31985959. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK553166\/. Accessed: July 1, 2024."},{"key":"648_CR2","doi-asserted-by":"publisher","first-page":"100052","DOI":"10.1016\/j.dadr.2022.100052","volume":"3","author":"KM Keyes","year":"2022","unstructured":"Keyes KM, Rutherford C, Hamilton A, Barocas JA, Gelberg KH, Mueller PP, Feaster DJ, El-Bassel N, Cerd\u00e1 M. What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? Using multiplier approaches to estimate prevalence for an unknown population size. Drug Alcohol Depend Rep. 2022;3:100052. https:\/\/doi.org\/10.1016\/j.dadr.2022.100052.","journal-title":"Drug Alcohol Depend Rep"},{"key":"648_CR3","doi-asserted-by":"publisher","first-page":"100557","DOI":"10.1016\/j.lana.2023.100557","volume":"23","author":"The Lancet Regional Health-Americas","year":"2023","unstructured":"The Lancet Regional Health-Americas. Opioid crisis: addiction, overprescription, and insufficient primary prevention. Lancet Reg Health Am. 2023;23:100557. https:\/\/doi.org\/10.1016\/j.lana.2023.100557.","journal-title":"Lancet Reg Health Am"},{"key":"648_CR4","doi-asserted-by":"publisher","first-page":"108350","DOI":"10.1016\/j.drugalcdep.2020.108350","volume":"218","author":"C Florence","year":"2021","unstructured":"Florence C, Luo F, Rice K. The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017. Drug Alcohol Depend. 2021;218:108350. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108350.","journal-title":"Drug Alcohol Depend"},{"key":"648_CR5","unstructured":"Jennings K. Economic Toll of Opioid Epidemic: $1.3 Trillion a Year. Forbes. https:\/\/www.forbes.com\/sites\/katiejennings\/2022\/02\/04\/economic-toll-of-opioid-epidemic-13-trillion-a-year\/. Accessed: July 1, 2024."},{"key":"648_CR6","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1111\/add.15963","volume":"117","author":"O Miron","year":"2022","unstructured":"Miron O, Barda N, Balicer R, Kor A, Lev-Ran S. Association of opioid use disorder with healthcare utilization and cost in a public health system. Addiction. 2022;117:2880\u20136. https:\/\/doi.org\/10.1111\/add.15963.","journal-title":"Addiction"},{"key":"#cr-split#-648_CR7.1","unstructured":"United States General Accounting Office (GOA). 2003. OxyContin Abuse and Diversion and Efforts to Address the Problem. GAO-04-110"},{"key":"#cr-split#-648_CR7.2","unstructured":"Washington, DC. https:\/\/www.gao.gov\/assets\/gao-04-110.pdf. Accessed: July 1, 2024."},{"key":"648_CR8","unstructured":"Nicholas R. (2019). Pharmaceutical opioids in Australia: A double-edged sword. National Centre for Education and Training on Addiction (NCETA), Flinders University, Adelaide. https:\/\/nceta.flinders.edu.au\/application\/files\/3616\/0156\/0373\/Pharmaceutical_opioids_in_Australia_A_double-edged_sword.pdf. Accessed: July 1, 2024."},{"key":"648_CR9","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/09687637.2021.1922609","volume":"29","author":"B Shapira","year":"2021","unstructured":"Shapira B, Rosca P. Mountain or molehill? A scoping review of evidence on an opioid use problem in Israel. Drugs: Educ Prev Policy. 2021;29:595\u2013603. https:\/\/doi.org\/10.1080\/09687637.2021.1922609.","journal-title":"Drugs: Educ Prev Policy"},{"key":"648_CR10","doi-asserted-by":"publisher","first-page":"e41621","DOI":"10.7759\/cureus.41621","volume":"15","author":"D Judd","year":"2023","unstructured":"Judd D, King CR, Galke C. The opioid epidemic: a review of the contributing factors, negative consequences, and best practices. Cureus. 2023;15:e41621. https:\/\/doi.org\/10.7759\/cureus.41621.","journal-title":"Cureus"},{"key":"648_CR11","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. (EMCDDA, 2024), European Drug Report 2024: Trends and Developments. https:\/\/www.emcdda.europa.eu\/publications\/european-drug-report\/2024_en. Accessed: July 1, 2024."},{"key":"648_CR12","doi-asserted-by":"publisher","first-page":"e2327488","DOI":"10.1001\/jamanetworkopen.2023.27488","volume":"6","author":"CM Jones","year":"2023","unstructured":"Jones CM, Han B, Baldwin GT, Einstein EB, Compton WM. Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021. JAMA Netw Open. 2023;6:e2327488. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.27488.","journal-title":"JAMA Netw Open"},{"key":"648_CR13","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/j.1526-4637.2009.00621.x","volume":"10","author":"P Shvartzman","year":"2009","unstructured":"Shvartzman P, Freud T, Singer Y, Brill S, Sherf M, Battat E, Vardy D. Opioid use in an Israeli health maintenance organization: 2000\u20132006. Pain Med. 2009;10:702\u20137. https:\/\/doi.org\/10.1111\/j.1526-4637.2009.00621.x.","journal-title":"Pain Med"},{"key":"648_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00228-010-0932-0","volume":"67","author":"AM Ponizovsky","year":"2011","unstructured":"Ponizovsky AM, Marom E, Zeldin A, Cherny NI. Trends in opioid analgesics consumption, Israel, 2000\u20132008. Eur J Clin Pharmacol. 2011;67:165\u20138. https:\/\/doi.org\/10.1007\/s00228-010-0932-0.","journal-title":"Eur J Clin Pharmacol"},{"key":"648_CR15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/pds.4415","volume":"27","author":"AM Ponizovsky","year":"2018","unstructured":"Ponizovsky AM, Marom E, Weizman A, Schwartzberg E. Changes in consumption of opioid analgesics in Israel 2009 to 2016: an update focusing on oxycodone and fentanyl formulations. Pharmacoepidemiol Drug Saf. 2018;27:535\u201340. https:\/\/doi.org\/10.1002\/pds.4415.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"648_CR16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1136\/rapm-2020-101924","volume":"46","author":"O Miron","year":"2021","unstructured":"Miron O, Zeltzer D, Shir T, Balicer RD, Einav L, Feldman BS. Rising opioid prescription fulfillment among non-cancer and non-elderly patients-Israel\u2019s alarming example. Reg Anesth Pain Med. 2021;46:455\u20136. https:\/\/doi.org\/10.1136\/rapm-2020-101924.","journal-title":"Reg Anesth Pain Med"},{"key":"648_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13584-023-00558-9","volume":"12","author":"B Shapira","year":"2023","unstructured":"Shapira B, Berkovitz R, Haklai Z, Goldberger N, Lipshitz I, Rosca P. Trends and correlated outcomes in population-level prescription opioid and transdermal fentanyl use in Israel. Isr J Health Policy Res. 2023;12:9. https:\/\/doi.org\/10.1186\/s13584-023-00558-9.","journal-title":"Isr J Health Policy Res"},{"key":"648_CR18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13584-023-00581-w","volume":"12","author":"RL Dressler","year":"2023","unstructured":"Dressler RL, Kaliner E, Cohen MJ. Trends in Israeli community-based opioid prescribing, 2010\u20132020, an observational study of the country\u2019s largest HMO. Isr J Health Policy Res. 2023;12:34. https:\/\/doi.org\/10.1186\/s13584-023-00581-w.","journal-title":"Isr J Health Policy Res"},{"key":"648_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13584-024-00598-9","volume":"13","author":"L Adler","year":"2024","unstructured":"Adler L, Cohen B, Shapiro Ben Daviv S, Liran O, Rahamim-Cohen D, Nakhleh A, Shahar A, Azuri J. Use of prescription opioids in Israel and socio-economic correlations between 2010 and 2020. Isr J Health Policy Res. 2024;13:12. https:\/\/doi.org\/10.1186\/s13584-024-00598-9.","journal-title":"Isr J Health Policy Res"},{"key":"648_CR20","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/0269216311398300","volume":"25","author":"K Svendsen","year":"2011","unstructured":"Svendsen K, Borchgrevink P, Fredheim O, Hamunen K, Mellbye A, Dale O. Choosing the unit of measurement counts: the use of oral morphine equivalents in studies of opioid consumption is a useful addition to defined daily doses. Palliat Med. 2011;25:725\u201332. https:\/\/doi.org\/10.1177\/0269216311398300.","journal-title":"Palliat Med"},{"key":"648_CR21","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/pds.4168","volume":"26","author":"S Nielsen","year":"2017","unstructured":"Nielsen S, Gisev N, Bruno R, Hall W, Cohen M, Larance B, Campbell G, Shanahan M, Blyth F, Lintzeris N, Pearson S, Mattick R, Degenhardt L. Defined daily doses (DDD) do not accurately reflect opioid doses used in contemporary chronic pain treatment. Pharmacoepidemiol Drug Saf. 2017;26:587\u201391. https:\/\/doi.org\/10.1002\/pds.4168.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"648_CR22","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s00520-023-08027-4","volume":"31","author":"S Menahem","year":"2023","unstructured":"Menahem S, Freud T, Batat E, Shvartzman P. Opioid consumption by cancer patients in an Israeli health maintenance Organization from 2007\u20132018. Support Care Cancer. 2023;31:560. https:\/\/doi.org\/10.1007\/s00520-023-08027-4.","journal-title":"Support Care Cancer"},{"key":"648_CR23","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1001\/jamapsychiatry.2021.0247","volume":"78","author":"M Fairley","year":"2021","unstructured":"Fairley M, Humphreys K, Joyce VR, Bounthavong M, Trafton J, Combs A, Oliva EM, Goldhaber-Fiebert JD, Asch SM, Brandeau ML, Owens DK. Cost-effectiveness of treatments for opioid use disorder. JAMA Psychiatry. 2021;78:767\u201377. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.0247.","journal-title":"JAMA Psychiatry"},{"key":"648_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13584-022-00551-8","volume":"12","author":"A Marom","year":"2023","unstructured":"Marom A, Levy I, Rosca P. Changes and trends in medication-assisted treatment in Israel. Isr J Health Policy Res. 2023;12:1. https:\/\/doi.org\/10.1186\/s13584-022-00551-8.","journal-title":"Isr J Health Policy Res"},{"key":"648_CR25","doi-asserted-by":"publisher","first-page":"100813","DOI":"10.1016\/j.lana.2024.100813","volume":"36","author":"AH H\u00e9bert","year":"2024","unstructured":"H\u00e9bert AH, Hill AL. Impact of opioid overdoses on US life expectancy and years of life lost, by demographic group and stimulant co-involvement: a mortality data analysis from 2019 to 2022. Lancet Reg Health Am. 2024;36:100813. https:\/\/doi.org\/10.1016\/j.lana.2024.100813.","journal-title":"Lancet Reg Health Am"},{"key":"648_CR26","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1159\/000485033","volume":"23","author":"D Feingold","year":"2017","unstructured":"Feingold D, Goldberger N, Haklai Z, Lev-Ran S. Fatal overdoses of opioids in Israel 2005\u20132014. Eur Addict Res. 2017;23:276\u201383. https:\/\/doi.org\/10.1159\/000485033.","journal-title":"Eur Addict Res"},{"key":"648_CR27","unstructured":"Rosca P, Spivak P, Goldman K, Austin O. (2020). Summary of the Activity of the Department for the Treatment of Substance Abuse for Year 2019 [Hebrew]. https:\/\/www.health.gov.il\/UnitsOffice\/HD\/MHealth\/mental\/addictions\/Documents\/mtl-addictions-2019.pdf. Accessed: July 1, 2024."},{"key":"648_CR28","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40471-019-00201-9","volume":"6","author":"S Slavova","year":"2019","unstructured":"Slavova S, Delcher C, Buchanich JM, Bunn TL, Goldberger BA, Costich JF. Methodological complexities in quantifying rates of fatal opioid-related overdose. Curr Epidemiol Rep. 2019;6:263\u201374. https:\/\/doi.org\/10.1007\/s40471-019-00201-9.","journal-title":"Curr Epidemiol Rep"},{"key":"648_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13584-024-00606-y","volume":"13","author":"MJ Cohen","year":"2024","unstructured":"Cohen MJ, Dressler RL, Kaliner E. Receipt of prescription opioid medication is associated with increased mortality in an Israeli population. Isr J Health Policy Res. 2024;13:17. https:\/\/doi.org\/10.1186\/s13584-024-00606-y.","journal-title":"Isr J Health Policy Res"},{"key":"648_CR30","doi-asserted-by":"publisher","unstructured":"Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain \u2014 United States, 2022. MMWR Recomm Rep. 2022;71(No. RR-3):1\u201395. https:\/\/doi.org\/10.15585\/mmwr.rr7103a1","DOI":"10.15585\/mmwr.rr7103a1"},{"key":"648_CR31","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12961-020-00596-8","volume":"18","author":"MS Jalali","year":"2020","unstructured":"Jalali MS, Botticelli M, Hwang RC, Koh HK, McHugh RK. The opioid crisis: a contextual, social-ecological framework. Health Res Policy Syst. 2020;18:87. https:\/\/doi.org\/10.1186\/s12961-020-00596-8.","journal-title":"Health Res Policy Syst"},{"key":"648_CR32","doi-asserted-by":"publisher","unstructured":"Spencer MR, Warner M, Cisewski JA, Mini\u00f1o A, Dodds D, Perera J, Ahmad FB. Estimates of drug overdose deaths involving fentanyl, methamphetamine, cocaine, heroin, and oxycodone: United States, 2021. Vital Statistics Rapid Release; no 27. Hyattsville, MD: National Center for Health Statistics. May 2023. https:\/\/doi.org\/10.15620\/cdc:125504","DOI":"10.15620\/cdc:125504"},{"key":"648_CR33","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1111\/add.15841","volume":"117","author":"H Jalal","year":"2022","unstructured":"Jalal H, Burke DS. Exponential growth of drug overdose poisoning and opportunities for intervention. Addiction. 2022;117:1200\u20132. https:\/\/doi.org\/10.1111\/add.15841.","journal-title":"Addiction"},{"key":"648_CR34","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1162\/ajhe_a_00101","volume":"4","author":"A Meinhofer","year":"2018","unstructured":"Meinhofer A. Prescription drug monitoring programs: the role of asymmetric information on drug availability and abuse. Am J Health Econ. 2018;4:504\u201326. https:\/\/doi.org\/10.1162\/ajhe_a_00101.","journal-title":"Am J Health Econ"},{"key":"648_CR35","doi-asserted-by":"publisher","first-page":"1356968","DOI":"10.3389\/fphar.2024.1356968","volume":"15","author":"M Khazen","year":"2022","unstructured":"Khazen M, Kamin-Friedman S. Overlooking the obvious: the importance of communicating safety and risks of opioids-the Israeli context. Front Pharmacol. 2022;15:1356968. https:\/\/doi.org\/10.3389\/fphar.2024.1356968.","journal-title":"Front Pharmacol"},{"key":"648_CR36","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(21)02252-2","volume":"399","author":"K Humphreys","year":"2022","unstructured":"Humphreys K, Shover CL, Andrews CM, Bohnert ASB, Brandeau ML, Caulkins JP, Chen JH, Cu\u00e9llar MF, Hurd YL, Juurlink DN, Koh HK, Krebs EE, Lembke A, Mackey SC, Larrimore Ouellette L, Suffoletto B, Timko C. Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission. Lancet. 2022;399:555\u2013604. https:\/\/doi.org\/10.1016\/S0140-6736(21)02252-2.","journal-title":"Lancet"},{"key":"648_CR37","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1001\/jama.2022.4017","volume":"327","author":"R Rubin","year":"2022","unstructured":"Rubin R, Suran M. Supervised consumption sites\u2014a tool for reducing risk of overdose deaths and infectious diseases in people who use illicit drugs. JAMA. 2022;327:1532\u20134. https:\/\/doi.org\/10.1001\/jama.2022.4017.","journal-title":"JAMA"},{"key":"648_CR38","doi-asserted-by":"publisher","unstructured":"Miron O, Wolff-Sagy Y, Levin M, Lubich E, Lewinski J, Shpunt M, Abu Ahmad W, Borochov I, Netzer D, Lavie G. Fentanyl initiation rate following the requirement for specialist approval. medRxiv 2024.03.13.24304188; https:\/\/doi.org\/10.1101\/2024.03.13.24304188","DOI":"10.1101\/2024.03.13.24304188"},{"key":"648_CR39","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1001\/archinte.161.1.85","volume":"161","author":"JH Samet","year":"2001","unstructured":"Samet JH, Friedmann P, Saitz R. Benefits of linking primary medical care and substance abuse services: patient, provider, and societal perspectives. Arch Intern Med. 2001;161:85\u201391. https:\/\/doi.org\/10.1001\/archinte.161.1.85.","journal-title":"Arch Intern Med"},{"key":"648_CR40","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1300\/J465v28n03_03","volume":"28","author":"TF Babor","year":"2007","unstructured":"Babor TF, McRee BG, Kassebaum PA, Grimaldi PL, Ahmed K, Bray J, Screening. Brief intervention, and Referral to Treatment (SBIRT): toward a Public Health Approach to the management of substance abuse. Substance Abuse. 2007;28:7\u201330. https:\/\/doi.org\/10.1300\/J465v28n03_03.","journal-title":"Substance Abuse"},{"key":"648_CR41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/17522439.2022.2057578","volume":"14","author":"A Friedlander","year":"2022","unstructured":"Friedlander A, Tzur Bitan D, Lichtenberg P. The Soteria model: implementing an alternative to acute psychiatric hospitalization in Israel. Psychosis. 2022;14:99\u2013108. https:\/\/doi.org\/10.1080\/17522439.2022.2057578.","journal-title":"Psychosis"},{"key":"648_CR42","unstructured":"Davidovitch N, Kranzler Y, Miron O. Are We Nearing an Opioid Epidemic in Israel? Taub Center for Social Policy Studies in Israel. 2023. https:\/\/www.taubcenter.org.il\/wp-content\/uploads\/2023\/03\/Opioids-2023-ENG.pdf. Accessed: July 1, 2024."},{"key":"648_CR43","doi-asserted-by":"publisher","first-page":"102418","DOI":"10.1016\/j.eclinm.2023.102418","volume":"68","author":"Y Levi-Belz","year":"2024","unstructured":"Levi-Belz Y, Groweiss Y, Blank C, Neria Y. PTSD, depression, and anxiety after the October 7, 2023 attack in Israel: a nationwide prospective study. EClinicalMedicine. 2024;68:102418. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102418.","journal-title":"EClinicalMedicine"},{"key":"648_CR44","doi-asserted-by":"publisher","unstructured":"Feingold D, Neria Y, Bitan DT. PTSD, distress and substance use in the aftermath of October 7th,2023 terror attacks in Southern Israel. J Psychiatr Res, 174:153\u20138 https:\/\/doi.org\/10.1016\/j.jpsychires.2024.04.022","DOI":"10.1016\/j.jpsychires.2024.04.022"},{"key":"648_CR45","unstructured":"Times of Israel. Israel sees sharp rise in addiction amid ongoing Gaza war. 2024. https:\/\/www.timesofisrael.com\/israel-sees-sharp-rise-in-addiction-amid-ongoing-gaza-war\/. Accessed: September 24, 2024."},{"key":"648_CR46","unstructured":"Doctors Only. Effects of War: A spike in anti-anxiety and narcotic painkillers. 2024. [Hebrew]. https:\/\/doctorsonly.co.il\/2024\/09\/326663\/. Accessed: September 24, 2024."},{"key":"648_CR47","doi-asserted-by":"publisher","first-page":"e233274","DOI":"10.1001\/jamahealthforum.2023.3274","volume":"4","author":"D Powell","year":"2023","unstructured":"Powell D. Educational attainment and US drug overdose deaths. JAMA Health Forum. 2023;4:e233274. https:\/\/doi.org\/10.1001\/jamahealthforum.2023.3274.","journal-title":"JAMA Health Forum"},{"key":"648_CR48","doi-asserted-by":"publisher","first-page":"108127","DOI":"10.1016\/j.drugalcdep.2020.108127","volume":"214","author":"J van Draanen","year":"2020","unstructured":"van Draanen J, Tsang C, Mitra S, Karamouzian M, Richardson L. Socioeconomic marginalization and opioid-related overdose: a systematic review. Drug Alcohol Depend. 2020;214:108127. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108127.","journal-title":"Drug Alcohol Depend"},{"key":"648_CR49","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41398-020-0847-1","volume":"10","author":"C Blanco","year":"2020","unstructured":"Blanco C, Wiley TRA, Lloyd JJ, Lopez MF, Volkow ND. America\u2019s opioid crisis: the need for an integrated public health approach. Transl Psychiatry. 2020;10:167. https:\/\/doi.org\/10.1038\/s41398-020-0847-1.","journal-title":"Transl Psychiatry"},{"key":"648_CR50","unstructured":"Truong TQ, Gandhi D, Rosenthal J et al. Tackling the Opioid Crisis Requires a Whole-of-Government, Society-Wide Approach. Center for American Progress. 2023. https:\/\/www.americanprogress.org\/article\/tackling-the-opioid-crisis-requires-a-whole-of-government-society-wide-approach\/. Accessed: July 1, 2024."}],"container-title":["Israel Journal of Health Policy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13584-024-00648-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13584-024-00648-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13584-024-00648-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T20:24:15Z","timestamp":1728591855000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijhpr.biomedcentral.com\/articles\/10.1186\/s13584-024-00648-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["648"],"URL":"https:\/\/doi.org\/10.1186\/s13584-024-00648-2","relation":{},"ISSN":["2045-4015"],"issn-type":[{"type":"electronic","value":"2045-4015"}],"subject":[],"published":{"date-parts":[[2024,10,10]]},"assertion":[{"value":"22 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}